Abstract:Background Non‐invasive evaluation of phosphomonoesters (PMEs) and phosphodiesters (PDEs) by 31‐phosphorus MR spectroscopy (31P MRS) may have potential for early therapy (non‐)response assessment in cancer. However, 31P MRS has not yet been applied to investigate the human pancreas in vivo. Purpose To assess the technical feasibility and repeatability of 31P MR spectroscopic imaging (MRSI) of the pancreas, compare 31P metabolite levels between pancreas and liver, and determine the feasibility of 31P MRSI in pancreatic cancer. Study Type Prospective cohort study. Population 10 healthy subjects (age 34 ± 12 years, four females) and one patient (73‐year‐old female) with pancreatic ductal adenocarcinoma. Field Strength/Sequence 7‐T, 31P FID‐MRSI, 1H gradient‐echo MRI. Assessment 31P FID‐MRSI of the abdomen (including the pancreas and liver) was performed with a nominal voxel size of 20 mm (isotropic). For repeatability measurements, healthy subjects were scanned twice on the same day. The patient was only scanned once. Test–retest 31P MRSI data of pancreas and liver voxels (segmented on 1H MRI) of healthy subjects were quantified by fitting in the time domain and signal amplitudes were normalized to γ‐adenosine triphosphate. In addition, the PME/PDE ratio was calculated. Metabolite levels were averaged over all voxels within the pancreas, right liver lobe and left liver lobe, respectively. Statistical Tests Repeatability of test–retest data from healthy pancreas was assessed by paired t‐tests, Bland–Altman analyses, and calculation of the intrasubject coefficients of variation (CoVs). Significant differences between healthy pancreas and right and left liver lobes were assessed with a two‐way analysis of variance (ANOVA) for repeated measures. A P‐value <0.05 was considered statistically significant. Results The intrasubject CoVs for PME, PDE, and PME/PDE in healthy pancreas were below 20%. Furthermore, PME and PME/PDE were significantly higher in pancreas compared to liver. In the patient with pancreatic cancer, qualitatively, elevated relative PME signals were observed in comparison with healthy pancreas. Data Conclusion In vivo 31P MRSI of the human healthy pancreas and in pancreatic cancer may be feasible at 7 T. Evidence Level 3 Technical Efficacy Stage 2

Metabolite Detection of Pancreatic Carcinoma by in Vivo Proton MR Spectroscopy at 3T: Initial Results Rilevazione Dei Metaboliti Del Carcinoma Pancreatico Mediante L'utilizzo in Vivo Della Spettroscopia Protonica a Risonanza Magnetica a 3T: Risultati Preliminari

Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results

Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation

Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome

31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data

Metabolic analysis using HR‐MAS in prostate tissue for prostate cancer diagnosis

Prediction of Metastasis of Prostate Cancer with Three-Dimensional Proton MR Spectroscopy:A Preliminary Study

In vivo MR spectroscopy for breast cancer diagnosis

Evaluation of Pancreatic Cancer by Multiple Breath-Hold Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 3.0T.

Preliminary Study of Proton MR Spectroscopy in Distinguishing Benign from Malignant Intracranial Lesions and Predicting the Malignancy of Tumors

Magnetic resonance fingerprinting of the pancreas at 1.5 T and 3.0 T

Quantitative Analysis of Prostate Adenocarcinoma by Magnetic Resonance Spectroscopy:Correlation Study with Systemic Biopsy

Metabonomic Studies of Pancreatic Cancer Response to Radiotherapy in a Mouse Xenograft Model Using Magnetic Resonance Spectroscopy and Principal Components Analysis

Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples

Pathologic characterization of human prostate tissue with proton MR spectroscopy.

Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues

Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T

In Vivo Hydrogen-1 Magnetic Resonance Spectroscopy Study of Human Intracranial Tumors.

An Update on MR Spectroscopy in Cancer Management: Advances in Instrumentation, Acquisition, and Analysis

Study of Single Voxel 1H MR Spectroscopy of Bone Tumors: Differentiation of Benign from Malignant Tumors.

Study of Metabonomic Profiles of Human Esophageal Carcinoma by Use of High-Resolution Magic-Angle Spinning 1H NMR Spectroscopy and Multivariate Data Analysis